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Abstract 
Posttranslational modification of substrate proteins by conjugation of SUMO regulates a 
diverse array of cellular processes. While predominantly a nuclear protein modification, there 
is growing appreciation that SUMOylation of proteins outside the nucleus plays direct roles 
in controlling synaptic transmission, neuronal excitability and adaptive responses to cell 
stress. Furthermore, alterations in protein SUMOylation are observed in a wide range of 
neurological and neurodegenerative diseases, and several extranuclear disease-associated 
proteins have been shown to be directly SUMOylated. Here, focusing mainly on 
SUMOylation of synaptic and mitochondrial proteins, we outline recent developments and 
discoveries, and present our opinion as to the most exciting avenues for future research to 
define how SUMOylation of extranuclear proteins regulates neuronal and synaptic function. 
Why is SUMOylation important? 
SUMOylation is essential in nearly all eukaryotes, and it regulates the functions and fates of 
hundreds of proteins in a wide variety of cell pathways (for recent overview of the 
‘SUMOsome’ see [1]). The consequences of SUMOylation are varied but the underlying 
principle is that it alters inter- and/or intramolecular interactions to change substrate protein 
localisation, stability, and/or activity. In neurons, rapid fine-tuning of protein function is 
essential to maintaining and modulating synaptic transmission and supporting synaptic 
plasticity. Importantly, a wide range of neuronal proteins, both nuclear and extranuclear, 
have been identified as SUMO substrates, and disrupting SUMO modification results in 
defects in synaptic plasticity, neuronal excitability and neuronal stress responses [2, 3]. 
Furthermore, a number of disease-associated proteins are SUMO substrates, and 
perturbations in SUMOylation have been observed in a variety of neurodegenerative 
disorders [2, 4]. Thus, SUMOylation has emerged as an essential regulator of neuronal 
function, and it is becoming increasingly apparent that SUMOylation may represent a novel 
therapeutic target in a wide range of diseases.  
In this Opinion article, focusing mainly on synaptic and mitochondrial proteins, we present an 




outstanding questions relating to how SUMOylation of extranuclear proteins regulates 
neuronal and synaptic function. 
SUMO conjugation 
In mammals, there are three ~11 kDa SUMO paralogues (SUMO1-3) that covalently 
conjugate to lysine residues, generally within a consensus motif in target proteins [5, 6]. 
SUMO2 and SUMO3 are identical except for three residues, but they share only ~50% 
sequence identity with SUMO1 [5]. Like ubiquitination, SUMO conjugation occurs via a 
three-step enzymatic pathway. SUMO propeptides are processed to expose a C-terminal di-
glycine motif and then ‘activated’ for conjugation by the E1 heterodimer of SAE1 and SAE2. 
Activated SUMO is passed to the E2 SUMO conjugating enzyme Ubc9 that, usually in 
concert with an E3 ligase, conjugates SUMO to the substrate protein [5]. In addition to being 
attached to substrates as monomers, SUMO proteins can also form diverse chains on 
substrate proteins through internal lysines, likely resulting in distinct outcomes for the 
modified target [2].   
SUMO deconjugation 
SUMOylation is a reversible modification, and SUMO can be removed from target proteins 
by SUMO proteases, nine of which have been identified [3] (Box 1). Thus, the extent and 
duration of substrate SUMOylation depend on a delicate balance between conjugation and 
SUMO protease-mediated deconjugation. Although relatively little is known about how 
SUMO proteases are regulated, given that there is only one E1 dimer, one E2, and a 
relatively small number of identified E3s for all SUMO conjugation [5, 6], it seems highly 
likely that the control of SUMO protease activity is a major contributor to determining how 
SUMOylation of individual targets, or subsets of them, is spatially and temporally regulated 
in response to external stimuli. 
Detection of SUMOylated proteins 
The identification and validation of SUMOylated target proteins is challenging due to low 
steady-state levels of endogenous protein modification and high levels of SUMO protease 
activity in cell lysates [7]. Nonetheless, advances in proteomic techniques have resulted in 
the identification of over 3500 substrate proteins [1], which are predominately nuclear and 
participate in processes such as transcription, chromatin remodelling, DNA repair and 
nucleocytoplasmic transport (for reviews see [8-10]).  
SUMOylation of neuronal proteins outside the nucleus 
As for other cell types, in neurons SUMOylation and deSUMOylation enzymes and 
SUMOylated target proteins are most highly enriched in the nucleus, and SUMOylation of 
nuclear proteins in neurons undoubtedly plays essential roles in neuronal differentiation, 
maturation and function [11]. However, many independent reports have confirmed that 
SUMOylation machinery and substrates are present and active in other neuronal 
compartments, including at synapses and mitochondria [2]. Indeed, numerous extranuclear 
proteins that are required for synaptic and mitochondrial function have been identified and 
functionally validated as targets of SUMOylation [2] (Figure 1). Nonetheless, the functional 
importance of SUMOylation at synapses is not universally accepted, and for instance, the 
existence of synaptic SUMO1-ylation in neurons has been questioned based on studies 
using an epitope-tagged SUMO1 knock-in mouse model [12, 13] (Box 2). 




Neurotransmitter release requires extremely precise spatial and temporal regulation, and 
manipulating presynaptic SUMOylation has profound effects on stimulation-evoked 
neurotransmitter release in isolated synaptosomal systems [14]. Identifying the specific 
presynaptic proteins that are SUMOylated in an activity-dependent and stimulus-specific 
manner, and defining the functional consequences for fine-tuning neurotransmitter release, 
is a formidable task. Nonetheless, several studies have identified individual presynaptic 
SUMOylation targets (Figure 2).  
RIM1α is required for vesicle priming, Ca2+ channel clustering near release sites and 
presynaptic plasticity [15]. RIM1α was the first component of the presynaptic release 
machinery identified as a SUMO target and it provided important new insight into how 
SUMOylation can regulate synaptic function and dysfunction [16]. More specifically, RIM1α 
SUMOylation acts as a molecular switch; SUMOylated RIM1α clusters Ca2+-channels 
necessary for depolarisation-evoked presynaptic Ca2+ signalling whereas non-SUMOylated 
RIM1α participates in the priming and docking of synaptic vesicles at the presynaptic active 
zone [16]. RIM1α also binds to synaptotagmin-1, a Ca2+ sensor in the presynaptic 
membrane, which is itself SUMOylated [17]. As yet, however, it is unclear if or how 
SUMOylation of one or both of these binding partners impacts on their interaction.  
Syntaxin1A is a component of the presynaptic SNARE machinery that provides most of the 
mechanical force for membrane fusion and neurotransmitter release [18]. Syntaxin1A is an 
activity-dependent SUMO substrate and preventing its SUMOylation increases rates of 
vesicle endocytosis but not the rate of exocytosis, providing a flexible SUMOylation-
mediated regulatory mechanism to control neurotransmitter release [19]. Furthermore, 
Synapsin1a, which anchors synaptic vesicles to the cytoskeleton and then releases them in 
response to depolarisation, is also a SUMO substrate. Preventing synapsin1a SUMOylation 
reduces the releasable vesicle pool and impairs neurotransmitter release [20].  
Taken together, these data demonstrate that several key components of the release 
machinery are regulated by SUMOylation and we have no doubt that more will be identified 
and characterised. Moreover, SUMOylation is emerging as an important component of other 
secretory systems, particularly for insulin release from pancreatic β-cells [21].  
SUMOylation of receptors and interacting proteins  
Kainate receptors (KARs) are a subclass of glutamate receptors present at both the pre- 
and postsynaptic membranes of subsets of excitatory synapses where they regulate 
synaptic formation, stabilisation and function [22]. The KAR subunit GluK2 was the first 
reported neurotransmitter receptor protein to be SUMOylated [23] and subsequent studies 
have shown that its SUMOylation is regulated by prior phosphorylation by PKC, and both 
modifications are required for agonist-induced KAR internalization and sustained depression 
of KAR-mediated responses at mossy fibre-CA3 synapses [24, 25].  
AMPA receptors (AMPARs) mediate most fast excitatory neurotransmission in the CNS 
and are critically important for nearly all aspects of brain function. In particular, regulated 
changes in the number and properties of AMPARs at synapses underlie long-term 
potentiation (LTP) and long-term depression (LTD) [26]. Although AMPARs have not been 
reported to be directly SUMOylated, SUMOylation plays a key role in activity-dependent 
AMPAR trafficking [27, 28].  
For example, suppression of action potentials with TTX induces homeostatic up-scaling of 
AMPARs [29], and this process can be blocked by overexpression of the SENP1 catalytic 




SUMOylation also plays a role in the initial insertion of AMPARs during LTP [27], since 
expression of the catalytic domain of SENP1, or of a dominant-negative Ubc9, blocks LTP 
induced chemically by application of the NMDA receptor co-agonist glycine [27]. 
Correspondingly, electrophysiological and in vivo behavioural studies have reported that 
acute inhibition of SUMOylation impairs LTP and hippocampal-dependent learning in mice 
[31] and neuron-specific knockdown of SUMO1-3 impairs episodic memory and fear 
conditioning, which rely on synaptic plasticity [32]. Thus, SUMOylation is required to support 
the AMPAR trafficking that underlies various forms of synaptic plasticity and memory 
formation. While these data are compelling, it is important to note that these studies relied 
on chronic perturbations of SUMOylation over many hours or days, so cannot conclusively 
distinguish whether the effects observed are due to direct modification of extranuclear or 
synaptic SUMO substrates, or due to changes in SUMOylation of nuclear proteins.   
Nonetheless, despite the evidence supporting a role for SUMOylation in AMPAR trafficking 
and synaptic plasticity, the direct targets mediating these effects have largely remained 
elusive. An identified example is Arc, which plays a key role in AMPAR endocytosis in 
homeostatic plasticity [33]. Arc is SUMOylated [30, 34] and overexpression of wild-type Arc, 
but not a non-SUMOylatable Arc mutant, prevents the TTX-evoked increase in AMPAR 
surface expression, consistent with a role in regulating AMPAR up-scaling [30]. It has also 
been proposed that SUMO1-ylated Arc forms a complex with the F-actin-binding protein 
drebrin A, leading to a hypothesis that newly synthesized Arc is SUMOylated and targeted 
for regulation of the actin cytoskeleton during in vivo LTP [35]. 
SUMOylation also has a role at inhibitory synapses. Gephyrin is part of a scaffolding protein 
complex that is required for postsynaptic clustering of GABAA receptors. Gephyrin is 
SUMOylated and it has been reported that its deSUMOylation promotes the formation of 
postsynaptic clusters via cross-talk between phosphorylation and acetylation of gephyrin 
[36]. 
Group III G protein-coupled metabotropic glutamate receptors (mGluR4, 6, 7 and 8) are 
predominantly presynaptic, where they act as autoreceptors to control neurotransmitter 
release [37]. All of the group III mGluRs contain a SUMOylation consensus motif in their 
intracellular C-termini and have been reported to be substrates for SUMOylation in vitro [38-
40]. Interestingly, in contrast to KARs, where SUMOylation is required for agonist-evoked 
endocytosis, it has been proposed that deSUMOylation enhances mGluR7 endocytosis, 
suggesting that SUMOylation stabilises the surface expression of mGluR7 in neurons [41]. 
However, it is noteworthy that, as for K2P1 channels (see below), this would infer that 
surface expressed mGluRs are stably SUMOylated, which does not fit well with the current 
concept of SUMOylation being a highly transient modification that acts mainly as a biological 
switch. 
SUMOylation of ion channels  
K2P1 channels provide a background potassium leak current that contributes to the resting 
membrane potential and reduces neuronal excitability. The K2P1 channel was the first ion 
channel reported to be SUMOylated, and preventing its SUMOylation unmasked K2P1 K+ 
conductance, implying that constitutive SUMOylation of K2P1 silences the channel [42] (but 
see also [43], a study that challenges whether K2P1 is SUMOylated). As noted for mGluRs, 
this is unusual given that SUMOylation is generally very transient and only a small 
proportion of most substrates are SUMOylated at any one time [7]. Nonetheless, prompted 




voltage-dependent potassium (Kv) channels, which also contribute to establishing resting 
membrane potential and to defining the duration and frequency of action potentials. 
SUMOylation of Kv1.5 was shown to regulate channel inactivation [44]. In this case, 
preventing SUMOylation causes a selective ~15 mV hyperpolarizing shift in the voltage-
dependence of steady-state inactivation with no associated effects on the voltage-
dependence of activation or total current density. Thus, whereas SUMOylation of K2P1 has 
been reported to completely prevent K+ conductance through the channel, SUMOylation of 
Kv1.5 has a more graded role. Furthermore, more recent studies have shown that 
SUMOylation decreases Kv2.1 [45], KV7.2 [46] and KV7.1 [47] K+ currents and, in contrast, 
SUMOylation of the voltage-dependent sodium channel NaV1.2 increases Na+ currents [48]. 
Taken together, these reports suggest that an overarching effect of ion channel 
SUMOylation can be to increase neuronal excitability by suppressing K+ channel activity as 
well as enhancing activity of Na+ channels.  
SUMOylation of mitochondrial proteins 
Neurons are highly energy-intensive cells as a result of the demands of maintaining 
membrane potential and supporting the ATP-dependent neurotransmitter release and 
receptor recycling machinery underpinning synaptic transmission. Accordingly, neurons 
contain an extensive and complex mitochondrial network. Individual mitochondria undergo 
frequent fusion and fission events as a quality control mechanism [49]. Drp1 is a GTPase 
that translocates from the cytosol to the mitochondrial outer membrane to mediate 
physiological fission and, under cell stress conditions, pathophysiological fragmentation and 
cytochrome c release that leads to apoptosis [50].  
Current evidence suggests that SUMO1-ylation stabilizes Drp1 [51] and enhances its 
recruitment to mitochondria to promote fragmentation and apoptosis [52]. Conversely, 
SUMO2/3-ylation reduces Drp1 recruitment to the mitochondria [53], at least in part by 
preventing binding to its main receptor mitochondrial fission factor (Mff). Thus, SUMO2/3-
ylation of Drp1 can act as an adaptive protective response in cell stress by decreasing 
cytochrome c release and apoptosis [54]. Interestingly, the extent and paralogue-specificity 
of Drp1 SUMOylation in neurons appears, at least in part, to be due to the activity of different 
SENP proteins. SENP2 knockout in mice results in neurodegeneration and mitochondrial 
defects, and leads to enhanced SUMO1 conjugation to Drp1 [55]. Conversely, in cultured 
cortical neurons, ischemic stress leads to degradation of the SUMO2/3 deconjugating 
enzyme SENP3, resulting in enhanced SUMOylation of Drp1 with SUMO2/3. This promotes 
Drp1 partitioning to the cytosol and subsequent neuronal survival [53]. Thus, the activity and 
levels of different SENPs can determine neuronal viability through regulating the 
SUMOylation status of Drp1.  
While this SUMO paralogue ‘switch’ concept on Drp1 is attractive, it should be noted that 
completely preventing Drp1 SUMOylation by mutating the target lysine residues promotes 
mitochondrial fragmentation and cell death [53, 54]. Alternatively, it could be that that 
SUMO1-ylation of proteins that bind to Drp1, rather than Drp1 itself, are involved in 
recruitment whereas SUMO2/3-ylation of Drp1 counters mitochondrial localisation. This 
situation is complicated by the observation that SUMO2/3-ylation of Fas-associated protein 
with Death Domain (FADD) in stressed conditions promotes its binding to Drp1 and this, in 
turn, promotes Drp1 recruitment by Mff [56].  
Thus, there is clearly a complex interplay of proteins and modifications that regulate Drp1-




provides a mechanism to tune the actions of Drp1 to correspond to the type and severity of 
cell stress.  
Concluding remarks 
Over the last 10 years, a concerted research effort has identified crucial roles for 
SUMOylation in controlling neuronal excitability, synaptic plasticity and survival. While 
SUMOylation of nuclear targets undoubtedly plays major roles, a large number of 
functionally validated extranuclear SUMOylation targets have also been demonstrated to 
play direct roles in regulating synaptic and mitochondrial function. Moreover, aberrations in 
SUMOylation are associated with multiple neuropathologies [2] (Box 4). Despite this 
progress, there remain many unanswered questions (see Outstanding Questions). 
For example, given the limited repertoire of SUMOylation enzymes, how is SUMOylation of 
specific substrates activity, spatially and temporally regulated to orchestrate neuronal 
function? More generally, the role of SUMOylation in protein network interactions is a widely 
applicable and largely open question. Many covalently SUMOylated proteins also possess 
SUMO interaction motifs (SIMs) that bind SUMO non-covalently [57] and can facilitate their 
binding to other SUMOylated proteins by acting as a molecular ‘glue’ to drive protein 
complex assembly. Thus, one way in which SUMOylation acts on protein networks is that, 
rather than proteins being individually SUMOylated, groups of proteins within a spatially 
defined network are SUMOylated en masse, a process known as ‘SUMO spray’ [58] (Box 3). 
In this scenario, the selective action of SUMO proteases could specify, collectively, the 
duration and location of proteins that remain SUMOylated in various cellular locations, as  
appears to be the case for Drp1 during ischemia [53, 54]. Moreover, given the recent 
questions that have arisen regarding the physiological role of SUMO1 conjugation at 
synapses, future studies examining the targets, regulation and paralogue specificity of 
SUMOylation of extranuclear substrate proteins will help clarify the breadth of roles played 
by SUMOylation outside the nucleus in neurons. 
Finally, investigating the roles of SUMOylation in the regulation of processes that are 
fundamental to healthy neuronal function, and are dysregulated over the lifespan or 
disrupted in brain diseases, will shed new light on mechanisms underpinning healthy aging 








AMPA receptors (AMPARs): α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptors are ionotropic glutamate receptors that mediate the vast majority of fast excitatory 
neurotransmission in the mammalian brain.  
APP: Amyloid precursor protein (APP) is a membrane protein that can be cleaved to 
generate beta amyloid (Aβ). Aβ can form amyloid plaques, which are a pathological hallmark 
of Alzheimer's disease. 
Aβ: Amyloid beta is the term encompassing a group of 36–43 amino acid peptides that are 
the main component of the amyloid plaques in Alzheimer's disease. 
DJ-1:  Protein deglycase DJ-1 (aka Parkinson disease protein 7), acts as a chaperone to 
inhibit α-synuclein aggregation under stressed conditions. Defects in DJ-1 are associated 
with early onset Parkinson’s disease 
Drp1:  A member of the dynamin family of GTPases that plays an integral role in 
mitochondrial quality control, maintenance and apoptotic pathways by promoting 
mitochondrial fission. 
FADD: Fas-associated protein with Death Domain is an adaptor protein that links specific 
receptors to procaspases that mediate apoptosis. 
Kainate receptors (KARs): Glutamate-activated ligand-gated ion channels that play key 
roles in modulating neurotransmitter release at the presynapse as well as neuronal 
excitability and synaptic transmission at the postsynapse. 
K2P1: The product of the KCNK1 gene, K2P1 is a two-pore potassium leak channel that 
contributes to resting membrane potential in neurons and was the first membrane protein 
shown to be a SUMO substrate.      
Posttranslational modification (PTM): Enzymatic attachment of chemical groups, lipids, 
sugars, or polypeptides to a protein after primary synthesis to modify its properties, 
interactions and/or functions.    
RIM1α: A presynaptic active zone protein, originally identified as a Rab3A interactor, which 
has a role in docking and trafficking of synaptic vesicles. 
SENPs:  A family of proteases that remove SUMO from target proteins. 
SUMO: Small ubiquitin-like modifier is a small protein that is covalently conjugated to lysines 
in target proteins to modify their properties. 
SUMOsome: Collective noun for the proteins that are capable of being SUMOylated, 
generally a term used in proteomics. 
Synapsin1a: A phosphoprotein that regulates the availability of synaptic vesicles for 
exocytosis.  
Synaptotagmin-1: A presynaptic Ca2+ sensing protein involved in vesicle docking and 
release.  
Syntaxin1A: A protein located at the presynaptic membrane that interacts with membrane 
associated SNAP-25 to form a receptor for the integral vesicle membrane protein, VAMP2, 
thereby forming a fundamental component of the vesicle fusion machinery. 
Ubc9: The only SUMO E2 conjugating enzyme.  
α-synuclein:  A protein abundantly expressed in the brain that is poorly understood but that 
may play a role in synaptic vesicle clustering in the presynaptic terminal. Mutant forms can 
form insoluble fibrils that contribute to neurodegenerative conditions such as Parkinson’s 







SUMOylation is a reversible covalent modification that allows for tight spatiotemporal control 
over substrate protein function. SUMO is deconjugated from target proteins by SUMO 
proteases. Nine mammalian SUMO proteases have been identified so far, but their specific 
targets and physiological roles remain relatively poorly characterised, and how SUMO 
protease activity is regulated to control substrate deSUMOylation is largely unknown (for 
recent reviews see [3, 59]).  
The largest family of SUMO proteases are the sentrin-specific proteases (SENPs). 
Generally, SENP1 and SENP2 mature pre-SUMOs and deconjugate SUMO1 and SUMO2/3, 
SENP3 and SENP5 preferentially deconjugate SUMO2/3, and SENP6 and SENP7 can edit 
polySUMO2/3 chains [60].  
Additionally, DeSUMOylating isopeptidases 1 and 2 (DeSI1 and DeSI2) have been identified 
[61]. DeSI1 seems highly specific, with only BTB-ZF identified as a substrate. The properties 
of DeSI2 have not been defined but, intriguingly, it exhibits a predominantly cytoplasmic 
rather than nuclear localisation [61]. Another recently identified but, as yet, largely 
uncharacterized SUMO protease is Ubiquitin-specific protease-like 1 (USPL1) [62]. 
What is clear, however, is that the extent and duration of substrate SUMOylation is 
intricately and dynamically balanced by conjugation and deconjugation. For example, 
regulation of the SUMO protease SENP3 directly controls the SUMO2/3-ylation status of the 
mitochondrial GTPase Drp1 [53, 54], supporting the concept that the stability, localisation 
and availability of SUMO proteases is a crucial process that determines the spatial and 
temporal SUMOylation of target proteins. 
Thus, given that the multiple identified SUMO proteases contrast sharply with the very few 
core enzymes that mediate SUMO conjugation, we hypothesise that regulation of SUMO 
proteases is a major contributor to determining how SUMOylation of individual or subsets of 
targets can be controlled in response to external stimuli. Further studies into how control of 
SUMO protease activity orchestrates neuronal SUMOylation at various cellular locations will 








Consensus and controversy: Absence of evidence or evidence 
of absence? 
While there is a consensus that most protein SUMOylation occurs within the nucleus, 
multiple classes of extranuclear SUMOylated proteins have been identified, as outlined in 
the text, and importantly, these have been functionally validated in neurons and other cell 
types. The target proteins include neurotransmitter receptors and associated proteins, 
transporters, ion channels, key components of the presynaptic release machinery and 
mitochondrial proteins (for reviews see [2, 63]). 
Notwithstanding these findings arising from many different labs, two related studies using a 
His6-HA-SUMO1 knock-in mouse model concluded that SUMO1-ylation of synaptic proteins 
does not occur to any significant extent [12, 13]. In the more recent paper of the two, 
SUMOylation of seven previously identified synaptic SUMO1 substrates was investigated – 
synapsin1a [20], gephyrin [36], GluK2 [23], syntaxin1a [19], RIM1α [16], mGluR7 [41], and 
synaptotagmin1 [17] – and no noticeable His6-HA-SUMO1-ylation of any of these proteins 
was detected in the His6-HA-SUMO1 knock-in mice [13]. Moreover, using subcellular 
fractionation and immunocytochemical staining, the authors similarly did not detect SUMO1-
ylation in synaptic fractions, or colocalisation of anti-SUMO1 signal with synaptic markers.  
It should be noted, however, that the mice used in these studies exhibit a 20-30% reduction 
in total SUMO1 conjugation [13], and – importantly, we would argue – the authors did not 
recapitulate the originally reported experiments in wild-type mice or rats. Indeed, it remains 
possible that the reduction in SUMO1 conjugation observed in these mice may be 
compensated for by SUMO2/3 conjugation, as occurs in SUMO1 knockout mice [64] – 
however, this possibility was not examined in the recent study [13]. We also note that the 
original studies reporting SUMOylation of synapsin1a [20], gephyrin [36], GluK2 [23], 
syntaxin1a [19], RIM1α [16] and mGluR7 [41] investigated the functional effects of 
SUMOylation. Thus, in addition to demonstrating SUMOylation biochemically, those studies 
demonstrated that SUMOylation affects the target functionally, something which was not 
addressed in the recent study questioning the functional role of SUMOylation at synapses.  
As set out in more detail elsewhere [65, 66], it seems likely that an underlying reason for the 
lack of synaptic protein SUMO1-ylation observed in the His6-HA-SUMO1 knock-in mouse 
studies is that this model system does not accurately report endogenous wild-type SUMO1-
ylation. The decrease in SUMO1 conjugation in the His6-HA-SUMO1 knock-in mice 
questions the assertion that there are no synaptic SUMO1-ylated proteins, and given these 
caveats, we believe these studies are not sufficiently definitive to cast doubt on the multiple 
lines of evidence pointing to the existence and functional relevance of synaptic SUMO1-







An intriguing concept based on quantitative mass spectrometry from experiments primarily 
investigating DNA repair is that SUMOylation can occur in parallel on individual proteins 
within a complex, or in the same immediate vicinity [58]. This has been termed “SUMO 
spray’ and may act to modulate multiple components of protein assemblies simultaneously. 
When this effect acts to hold complexes together it has been called “SUMO velcro”. This is 
an attractive hypothesis because it bypasses the requirement for specific SUMOylation of 
particular proteins in a particular compartment, which is difficult to reconcile with the fact that 
there is only one E1 dimer and one E2 enzyme for SUMO1- and SUMO2/3-ylation. That is, if 
SUMOylation pathways are available and activated, presumably all appropriate target 
proteins in the vicinity will be modified.   
There is precedent for this idea in DNA double-strand break repair since DNA damage 
triggers a SUMOylation wave, leading to simultaneous multisite modifications of several 
repair proteins in the same pathway. This synergistic SUMOylation of several proteins 
stabilizes physical interactions to promote efficient DNA repair in response to specific 
triggers [58]. 
It is tempting to extend this SUMO spray concept to extranuclear compartments such as the 
pre- and postsynapse and mitochondria, where functional clusters or networks of proteins 
are likely to be subject to simultaneous SUMOylation. For example, as outlined in the main 
text, at the presynapse, neurotransmitter release requires highly coordinated protein-protein 
interactions and multiple presynaptic proteins are SUMO substrates. Moreover, 
SUMOylation of Drp1 at mitochondria could be accompanied by SUMOylation of other 
proteins in the Drp1 network that, together, regulate mitochondrial fission, particularly under 
stressed conditions. Indeed, it has been reported that the FADD protein is SUMOylated and 
it is possible that other SUMOylated proteins in this pathway will be identified in the future. 
Although appealing, this concept is currently difficult to assess at mitochondria or at the 
presynapse because there is an insufficient arsenal of tools to monitor the SUMOylation 
status of multiple proteins in unison. Nonetheless, we expect rapid progress in this area and 
that it will soon be possible to investigate how SUMOylation of groups of proteins is 
orchestrated to exert adaptive responses such as in synaptic plasticity and cytoprotection 








SUMOylation and disease 
SUMOylation plays key roles in regulating processes that are fundamental to healthy 
neuronal function. The converse is that dysregulation of protein SUMOylation is strongly 
implicated in neurological and neurodegenerative diseases. Furthermore, there is mounting 
evidence that cell stress-induced increases in protein SUMO2/3-ylation may represent an 
adaptive neuroprotective response (for recent reviews see [2, 67]). 
An example of this is the growing consensus that SUMOylation plays an important 
neuroprotective role in response to ischemia. Animals that hibernate endure prolonged 
ischaemia and subsequent reperfusion but emerge undamaged. Intriguingly, SUMOylation is 
massively increased during torpor [68] and in ischaemia, and this has been proposed as a 
cytoprotective response [68-70]. One mechanism appears to be stress-related modulation of 
SENP3, which regulates the SUMOylation status and mitochondrial recruitment of Drp1, a 
protein that plays a key role in ischemia and reperfusion injury [3, 53], such as occurs in 
stroke and preeclampsia, that can cause foetal brain damage, epilepsy and autism [71]. 
SUMOylation of mitochondrial proteins is also directly relevant to Parkinson’s disease (PD), 
Alzheimer’s disease (AD) and other dementias in which mitochondrial dysfunction is a major 
factor [72, 73]. Three proteins implicated in familial PD (α-synuclein [74], DJ-1 [75] and 
Parkin [76]) have each been reported to be either covalently SUMOylated or associate with 
SUMO. These proteins regulate mitochondrial dynamics [77] and, interestingly, ablation of 
DJ-1 enhances SUMO-1-ylation of Drp1, leading to excessive mitochondrial fission, 
suggesting DJ-1 may be protective by regulating Drp1 SUMOylation [78]. Dysregulation of 
SUMOylation has been reported in AD and the Tg2576 transgenic AD mouse model [79], 
and the AD-associated proteins APP and tau have been reported to be directly SUMOylated 
[80-83]. Furthermore, Aβ oligomers impair activity-dependent upregulation of SUMOylation, 
and enhancing SUMOylation rescues Aβ-induced deficits in LTP and learning and memory 
tasks [79].  
A characteristic factor in multiple neurodegenerative disorders is the accumulation and 
aggregation of disease-associated proteins in affected neurons and, in many cases, 
SUMOylation of the associated protein has been implicated in regulating its stability and 
solubility [84]. For example, α-synuclein accumulates into Lewy Bodies in PD and associated 
disorders, and SUMOylation of α-synuclein is strongly implicated in regulating α-synuclein 
solubility, although whether it promotes or reduces aggregation remains controversial [74, 
85, 86]. Furthermore, PolyQ expansions in disease-associated proteins lead to the formation 
of aggregates in Huntington’s Disease [87-89], spinobulbar muscular atrophy [90], 
dentatorubral-pallidoluysian atrophy [91] and a number of spinocerebellar ataxias [92-94], 
and several of the affected proteins have been reported to be modified by SUMO, resulting 
in altered solubility of the target protein. 
Taken together, this large and growing body of evidence suggests that SUMOylation plays 
critical, but as yet ill-defined roles in the onset, progression and manifestation of many 
different diseases. Defining the precise mechanisms involved and generating novel 





  Protein Function Role of SUMOylation References 
Presynaptic Proteins 
RIM1α 
Presynaptic protein required for vesicle 
priming and calcium channel clustering 
near release sites 




Presynaptic calcium sensor involved in 




Presynaptic SNARE protein that provides 
mechanical force for fusion of synaptic 
vesicles with the plasma membrane 
Alters the balance of synaptic vesicle endo- 




Anchors synaptic vesicles to the 
cytoskeleton to maintain the reserve 
vesicle pool 
Enhances SynIa association with synaptic 
vesicles to promote the efficient 
reclustering of SynIa following neuronal 
stimulation  
[20] 
Group III mGluRs 
(mGluRs 4, 6, 7 
and 8) 
Presynaptic G-protein-coupled glutamate 
receptors 
In the case of mGluR7, stabilizes mGluR7 




Component of kainate-type glutamate 
receptors 
Promotes endocytosis of GluK2-containing 
receptors in response to agonist 
[23] 
Arc 
Cytoskeletal-associated protein involved in 
endocytosis of AMPARs 
Arc SUMOylation is required for 
homeostatic upscaling of AMPARs. 
Promotes association of Arc with the actin-
binding protein Drebrin A 
[30, 35] 
Gephyrin 
Postsynaptic scaffold at inhibitory synapses 
that plays a critical role in scaffolding 
GABAA receptors 







K2P1 Potassium leak channel 
SUMOylation blocks ion flow through the 
channel 
[42] 
Kv1.5 Voltage-gated potassium channel 
Affects the voltage-dependence of steady-
state inactivation 
[44] 
Kv2.1 Voltage-gated potassium channel 
Increases the half-maximal activation 
voltage, reducing channel activity 
[45] 
KV7.1 Voltage-gated potassium channel 
Increases the half-maximal activation 
voltage, reducing channel activity 
[47] 
KV7.2 Voltage-gated potassium channel 
Reduces the KV7.2-dependent 
hyperpolarizing M-current 
[46] 
NaV1.2 Voltage-gated sodium channel 
Affects voltage-dependence of channel 




Drp1 GTPase that mediates mitochondrial fission 
Controls Drp1 partitioning to mitochondria; 
SUMO1-ylation promotes mitochondrial 




Adaptor protein involved in the induction of 
apoptosis 
Enhances binding to Drp1, promoting 










Figure 1. Subcellular localisation of SUMO machinery and SUMO targets in neurons. 
Substrate proteins for SUMOylation and components of the SUMOylation machinery can be 
found throughout neurons. The schematic highlights where components of the SUMO 
machinery have been shown to be localised (left hand dotted box), and the diverse cellular 
locations of known SUMO substrates (right hand dotted box). While the majority of known 
SUMO substrates are nuclear, pre- and postsynaptic proteins are also SUMOylated (see 
also Figure 2). At the presynapse, SUMOylation alters the function of various proteins 
involved in neurotransmitter release, to control the efficacy of synaptic transmission. At the 
postsynapse, SUMOylation regulates the activity of receptors and scaffolding proteins. 
Moreover, SUMOylation of several classes of ion channels localised at the plasma 
membrane alters their activity and tunes neuronal excitability. Finally, SUMOylation of the 
mitochondrial proteins Drp1 and FADD plays roles in mitochondrial dynamics and in 
neuronal responses to stress. For more details see also Table 1. Figure generated from 
shapes available from Servier Medical Art (https://smart.servier.com/) under a Creative 








Figure 2. Functional consequences of synaptic SUMOylation 
SUMOylation and deSUMOylation of target proteins at synapses has profound effects on 
synaptic function. Known SUMO substrates localised to the presynapse (top), as well as to 
excitatory or inhibitory postsynapses (bottom left/right, respectively) are shown. SUMO-
modified species are represented with a red SUMO moiety attached. In the schematic axon 
terminal and presynapse (top), known SUMO substrates are highlighted. SUMOylation of 
RIM1α alters its function by facilitating calcium channel clustering to promote 
neurotransmitter release. SUMOylation of Synapsin1a is required to maintain the 
cytoskeleton-associated releasable pool of synaptic vesicles by enhancing the interaction 
between Synapsin1a and the synaptic vesicles, while Syntaxin1a SUMOylation increases 
the rate of vesicle endocytosis at the presynaptic membrane. Furthermore, the presynaptic 
glutamate receptor mGluR7 is stabilised at the cell surface by SUMO modification.  
At excitatory postsynapses (bottom left), SUMOylation of Arc enhances its recruitment to the 
cytoskeleton via the actin-binding protein drebrin A and reduces its ability to promote 
AMPAR endocytosis. The kainate receptor subunit GluK2 is SUMOylated upon agonist 
binding, driving its internalisation to depress KAR-mediated synaptic responses. At inhibitory 
postsynapses (bottom right), gephyrin deSUMOylation favours the formation of postsynaptic 
GABAAR clusters. Figure generated from shapes available from Servier Medical Art 
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